Unraveling how much of a prescription drug price gets swallowed by āmiddlemenā is at the forefront of Tuesdayās drug price hearing in the Senate. One thing bound to come up: rebates.
Both major political parties have shown interest in remedying high drug prices, and drugmakers have bemoaned how rebates to middlemen keep them from reaping every dollar associated with those price tags.
Pharmacy giant the Trump administrationās proposal to end these post-transaction discounts as they apply to Medicare. Yet, in January the company rolled out a Medicare drug plan that experts say is similar āin spiritā to the administrationās proposal.
The CVS Caremark plan wasnāt popular with customers, and CVS Health, which owns CVS Caremark, was quick to point this out as evidence that consumers prefer the current rebate system.
āWe had a very, I would say, small number of seniors enroll in that program,ā Larry Merlo, CVS Healthās CEO on a February earnings with investors. āAnd we think one of the barriers to that was the increase that we saw in the monthly premium.ā
The CVS planās premium was $80 a month, which is about the average Medicare Part D monthly charge. But since it is designed to pass on a portion of rebates directly to patients at the pharmacy counter, certain patients would wind up with smaller out-of-pocket costs than they previously paid.
āEven very well-informed consumers would not necessarily understand that a higher premium plan in this case means that theyāre incurring smaller amounts at the point of sale,ā said Rachel Sachs, an associate law professor at Washington University in St. Louis who specializes in health care.
So why did only 25,000 people sign up for the plan, called ? Either consumers didnāt want the plan or perhaps they just didnāt understand it.
Weāll break it down for you.
Untangling Jargon: The Way Things Are And How They Could Change
A pharmacy benefit manager, or PBM, handles drug claims for health insurance companies. The big ones are Express Scripts, CVS Caremark and OptumRx. Every time you fill a prescription and use your drug plan, your PBM is involved in paying the claim and determining how much money you owe the cashier.
A rebate is a discount the PBM negotiates with a drug manufacturer off the price the drugmaker sets, which is called a list price. Rebates are not made public, and they typically donāt get passed on to the patient at the pharmacy counter in the form of a lower copayment, experts say.
When the drugmaker eventually pays the rebate back to the PBM, the PBM often uses this money to lower premiums, which are the monthly fees that Medicare Part D plans charge beneficiaries. They differ for each drug plan.
In a way, patients taking drugs with high list prices and big rebates wind up subsidizing other patientsā premiums, said Erin Trish, the associate director of the University of Southern California Schaeffer Center for Health Policy and Economics. Premiums on average havenāt substantially increased in more than a decade, but it may be āunfairā to the patients paying higher prices for drugs at the pharmacy counter.
āSome may argue, āTheyāre sickerā¦ Maybe they should [pay more],āā Trish said. āLook. We decided everyone should pay the same premium in this market. [Rebates] shouldnāt be a roundabout way to make a subset of beneficiaries pay more.ā
That could all change under a new Trump administration proposal that would ban rebates as they exist today. The negotiated discounts would be applied at the pharmacy counter, meaning discounts would be passed on to patients as out-of-pocket costs that are calculated based on the discounted price, not the higher list price.
For patients taking drugs with high list prices and large rebates, like insulin, it could mean noticeable savings, Sachs said. For patients taking drugs without big rebates, like generics or brand-name drugs without other branded competition, theyāre not likely to see much change at the pharmacy counter.
Everyone, however, will see premiums go up. Itās unclear yet how much, but Trish said the SilverScript Allure plan CVS Caremark is offering isnāt necessarily the best indicator. Consultants hired by the Department of Health and Human Services premiums will go up $3.20 to $5.64 per month if the rule takes effect in 2020. The average Medicare Part D premium for 2019 was $41.21, according to the Kaiser Family Foundation. (Kaiser Health News is an editorially independent program of the foundation.)
So Why Didnāt Patients Want The CVS Caremark Plan?
Itās not clear how well seniors shopping for drug plans understood the SilverScript Allure plan, among their many options. They could see it had a high premium, but no deductible. They might not have realized it required smaller payments on drugs at the pharmacy counter.
that the premium is the most important factor seniors consider when choosing a plan, Sachs said.
On top of that, people are unlikely to leave their current plans even if thereās a better one available.
Whatās more, we donāt know how well CVS Caremark marketed the plan to seniors who would benefit. They wouldnāt tell us, despite multiple calls and emails.
OptumRx, a competing PBM, started offering customers similar discounts at the pharmacy counter ā but for people with commercial insurance, not Medicare or Medicaid. Unlike CVS Caremark, it has a web page with basic language, like āpoint of sale discounts mean lower costs,ā and a link to request more information about switching. OptumRx did not respond to a request for comment.
PBMs: Helping Or Hurting?
Rebates for individual plans and drugs are confidential, but in Medicare Part D, theyāve increased on average from 9.6% of total spending in 2007 to 19.9% in 2016, according to annual reports to the Medicare boards of trustees.
So itās perhaps unsurprising the brand-name drug trade group, the Pharmaceutical Research and Manufacturers of America, said it āapplaud[s]ā the proposal to overhaul the rebate system. PhRMA says it pushes them to raise prices in order to offer larger rebates, because drugs with larger rebates often get preferential treatment by PBMs.
Still, PBMs offer the benefit of batting down net prices (the price after rebate), and keeping down drug spending overall.
There are multiple estimates on how much the rebate proposal would cost the Centers for Medicare & Medicaid if it took effect, and they indicate that unless there are other changes to Medicare Part D, it would likely cost more money than the current system, Sachs said.
āIt is startling to see the administration moving forward so rapidly with this proposal without a better understanding of how different actors might respond,ā she said. As a result, thereās a āhuge amount of uncertaintyā over how this could all play out.
